An analysis of anticoagulant adverse drug events in a large community teaching hospital

2007 ◽  
Vol 25 (1) ◽  
pp. 121-121
Author(s):  
Z. Khudeira ◽  
Satish Jain
Keyword(s):  
Teaching Hospital ◽  
Adverse Drug Events ◽  
Large Community ◽  
Community Teaching

M1432: Qualitative Evolution of Colonoscopy - An Analysis Over 10 Years of Continuous Practice At a Large Community, Teaching Hospital

2010 ◽  
Vol 71 (5) ◽  
pp. AB219-AB220
Author(s):  
Arjun Vaid ◽  
Mariann Padron ◽  
Brenda Jimenez ◽  
Roger D. Mitty
Keyword(s):  
Teaching Hospital ◽  
Large Community ◽  
Qualitative Evolution ◽  
Community Teaching

scholarly journals Protected code blue: using in situ simulation to develop a protected code blue and modify staff training protocol—experience in a large community teaching hospital during the COVID-19 pandemic

2021 ◽  
Vol 10 (1) ◽  
pp. e001097
Author(s):  
Fady A Youssef ◽  
Monique Patel ◽  
Hyunsoon Park ◽  
Jay V Patel ◽  
James Leo ◽  
...  
Keyword(s):  
Teaching Hospital ◽  
Healthcare Workers ◽  
Care Delivery ◽  
Control Measures ◽  
High Exposure ◽  
In Situ Simulation ◽  
Team Members ◽  
Large Community ◽  
Code Blue ◽  
Community Teaching

The surge in clinical demand, shortage in personal protective equipment and high-exposure risk for healthcare workers during the COVID-19 pandemic has challenged hospital common practices and forced a reassessment of care delivery models. Code blue teams are highly specialised units that partake in life-saving situations that can jeopardise the safety of team members. There is a paucity of guidance in regards to proper infection control measures to protect the responders.This study describes a methodical approach to assessing vulnerabilities to transmission of SARS-CoV-2 within existing code blue practices, modalities to limit the number of code blue team responders and modifications to the protocol at a large community teaching hospital. The effort undertaken faced challenges due to the nature of the pandemic and the increased demand on healthcare workers. Quality improvement methods facilitated our protocol design and implementation. To this date, there has been no identified COVID-19 disease in any protected code blue (PCB) team members. We recommend that similar practices be considered and adopted widely and practised periodically.

scholarly journals 1994. Impact of Pharmacist-initiated MRSA Nasal PCR Protocol on Pneumonia Therapy in a Community Teaching Hospital

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S669-S669
Author(s):  
Selena Pham ◽  
Abby Sturm ◽  
Lisa Dumkow ◽  
Joshua Jacoby ◽  
Nnaemeka Egwuatu
Keyword(s):  
Median Time ◽  
Teaching Hospital ◽  
Adverse Drug Events ◽  
Kidney Injury ◽  
Nasopharyngeal Swab ◽  
Protocol Implementation ◽  
Before And After ◽  
Quasi Experimental ◽  
The Impact ◽  
Community Teaching

Abstract Background Methicillin-resistant Staphylococcus aureus (MRSA) nasal PCR testing can rapidly detect MRSA colonization via nasopharyngeal swab. With a high negative predictive value for MRSA pneumonia, this test may help minimize the duration of anti-MRSA therapy and associated adverse drug events. This study aimed to evaluate the impact of a pharmacist-initiated MRSA nasal PCR protocol on pneumonia therapy in a community teaching hospital. Methods This retrospective, quasi-experimental study evaluated adult patients with pneumonia before and after the implementation of a pharmacist-initiated MRSA nasal PCR protocol. The GeneXpert MRSA/SA Nasal Complete Assay was utilized for PCR testing. Prior to protocol implementation the MRSA nasal PCR was not routinely used to assist in pneumonia treatment decisions. Following protocol implementation, pharmacists ordered MRSA PCR testing after an order for anti-MRSA pneumonia therapy; however, prescriber approval was required to discontinue therapy following negative result. The primary outcome of this study was to compare the duration of anti-MRSA therapy between the pre-PCR group (June 1–November 1, 2017) and PCR group (June 1–November 1, 2018). Secondary comparisons included the duration of antipseudomonal therapy, time from IV to PO interchange, adverse events, and clinical outcomes between groups. Results 210 patients were included (pre-PCR n = 138, PCR n = 72). Vancomycin was the anti-MRSA therapy ordered for all patients in both groups. In the PCR group, the median time from vancomycin order to PCR order was 2.8 hours (0–45.6 hours), while median time from PCR order to PCR result was 4.4 hours (0.6–31.5 hours). The PCR result was negative for 63 patients (87.5%) and 56 (88.9%) vancomycin orders were discontinued within 24 hours of the negative result. The mean duration of vancomycin therapy was significantly shorter in the PCR group (2.5 vs. 1.4 days, P < 0.001) as well as duration of IV therapy (5 vs. 3.9 days, P = 0.003). There was no difference between groups in duration of antipseudomonal therapy (P = 0.425), acute kidney injury (P = 0.332), 30-day readmission (P = 0.137), or 30-day mortality (P = 0.179). Conclusion A pharmacist-led MRSA nasal PCR protocol significantly decreased the duration of anti-MRSA therapy and IV antibiotic duration in patients with pneumonia. Disclosures All authors: No reported disclosures.

Evaluation of a Pharmacy-Managed Pharmacokinetic Dosing Program

2014 ◽  
Vol 28 (6) ◽  
pp. 529-534 ◽  
Author(s):  
Lyndsi K. Meyenburg ◽  
Andrew J. Crannage ◽  
Julie A. Murphy ◽  
Matthew J. Korobey
Keyword(s):  
Creatinine Clearance ◽  
Teaching Hospital ◽  
Financial Outcomes ◽  
Large Community ◽  
Additional Support ◽  
The Impact ◽  
Community Teaching

Purpose: The objective of this study was to determine the impact of a pharmacy-managed pharmacokinetic dosing program on appropriate dosing of famotidine, enoxaparin, and ketorolac. Methods: A large community teaching hospital implemented a pharmacy-managed pharmacokinetic dosing program for famotidine, enoxaparin, and ketorolac. Subjects were included if they received famotidine and had a creatinine clearance (CrCl) of <50 mL/min; received therapeutic enoxaparin and had a CrCl of <30 mL/min; or received ketorolac and had a CrCl <30 mL/min, age > 65 years or weight <50 kg. Results: One hundred and forty-six patients were included in the preimplementation group (famotidine [n = 50], enoxaparin [n = 46], and ketorolac [n = 50]) and 143 patients were included in the postimplementation group (famotidine [n = 50], enoxaparin [n = 43], and ketorolac [n = 50]). In all, 66% of patients were dosed appropriately in the preimplementation group (famotidine 28%, enoxaparin 85%, and ketorolac 86%) compared to 94% in the postimplementation group (famotidine 92%, enoxaparin 95%, and ketorolac 94%), P < .001. Conclusion: Implementation of a pharmacy-managed pharmacokinetic dosing program significantly improved appropriate dosing of famotidine, enoxaparin, and ketorolac. These findings could justify expansion of pharmacist autonomy through institution–approved, pharmacy-managed programs for other medications to improve appropriate dosing. Analyses specifically evaluating patient-oriented or financial outcomes may provide additional support for expansion.

Evaluation of a capped dosing telavancin regimen compared to standard dosing at a large community teaching hospital

2021 ◽  
Author(s):  
Fernando J. Diggs ◽  
Jonathan D. Edwards ◽  
Kimberly B. Garza ◽  
Ali A.M. Hassoun ◽  
Spencer H. Durham
Keyword(s):  
Body Weight ◽  
Adverse Effects ◽  
Teaching Hospital ◽  
Total Body Weight ◽  
Obese Patients ◽  
Dosing Regimen ◽  
Large Community ◽  
Total Body ◽  
Community Teaching ◽  
Equal Efficacy

Telavancin, a lipoglycopeptide antibiotic, is traditionally dosed as 10 mg/kg based on total body weight, but is associated with toxicities that limit its use. This study supports the use of a capped dosing regimen of 750 mg in obese patients, which is associated with equal efficacy and fewer adverse effects compared to traditional dosing.

scholarly journals Development and Implementation of a Combined Master of Science and PGY1/PGY2 Health-System Pharmacy Administration Residency Program at a Large Community Teaching Hospital

2018 ◽  
Vol 53 (2) ◽  
pp. 96-100 ◽  
Author(s):  
Nicholas P. Gazda ◽  
Emily Griffin ◽  
Kasey Hamrick ◽  
Jordan Baskett ◽  
Meghan M. Mellon ◽  
...  
Keyword(s):  
Health System ◽  
Health Systems ◽  
Teaching Hospital ◽  
Medical Center ◽  
Degree Programs ◽  
Master Of Science ◽  
Pharmacy Administration ◽  
Large Community ◽  
High Level ◽  
Community Teaching

Purpose: The purpose of this article is to share experiences after the development of a health-system pharmacy administration residency with a MS degree and express the need for additional programs in nonacademic medical center health-system settings. Summary: Experiences with the development and implementation of a health-system pharmacy administration residency at a large community teaching hospital are described. Resident candidates benefit from collaborations with other health-systems through master’s degree programs and visibility to leaders at your health-system. Programs benefit from building a pipeline of future pharmacy administrators and by leveraging the skills of residents to contribute to projects and department-wide initiatives. Tools to assist in the implementation of a new pharmacy administration program are also described and include rotation and preceptor development, marketing and recruiting, financial evaluation, and steps to prepare for accreditation. Conclusion: Health-system pharmacy administration residents provide the opportunity to build a pipeline of high-quality leaders, provide high-level project involvement, and produce a positive return on investment (ROI) for health-systems. These programs should be explored in academic and nonacademic-based health-systems.

Sign in / Sign up

Export Citation Format

Share Document